Optimizing patient flow and capacity is one of the most important strategic priorities for healthcare organizations, due to ...

AI tools designed to assist in medical decisions may not treat all patients equally. A new study shows that these systems ...

Clinical approaches to non-Hodgkin lymphoma in younger and older patient groups generally do not differ, according to Andrew Evens, DO, but he emphasized the need for deeper clinical insights into ...

Hospitals, clinics and other healthcare facilities are all about people, yet the industry is burdened with issues of access, ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

Chemotherapy regimens chosen by the ChemoID assay dramatically increased ORR in patients with platinum-resistant ovarian ...

CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, ...

A key theme at the AD/PD 2025 has been the safety profile of DMTs, focusing on the issue of ARIA, a significant side effect of the Aβ mAb drug class.

Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...

The "Healthcare Providers Global Industry Almanac 2020-2029" report has been added to ResearchAndMarkets.com's offering. The global healthcare providers market recorded revenues of $11.59 billion in ...

The ongoing ACESOT-1051 (A Multi-Center Evaluation of WEE1 Inhibitor in Patients with Advanced Solid Tumors ... "We are pleased with the progress of the trial and encouraged by the safety profile of ...